Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate whether armodafinil at a target dosage of
200 mg/day is more effective than placebo treatment in improving excessive sleepiness in
patients with obstructive sleep apnea/hypopnea syndrome (OSAHS) who have comorbid major
depressive disorder or dysthymic disorder.